MedTrace Logo

Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

NCT01224769 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2010-10-21

No results posted yet for this study

Summary

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

Conditions

  • Relapsed or Refractory Chronic Lymphoproliferative Disorders

Interventions

DRUG

bendamustine +/- rituximab

Sponsors & Collaborators

  • Gruppo Italiano Studio Linfomi

    lead OTHER

Principal Investigators

  • Emilio Iannitto, MD · Gruppo Italiano Studio Linfomi

  • Fortunato Morabito, MD · Gruppo Italiano Studio Linfomi

  • Stefano Luminari, MD · Gruppo Italiano Studio Linfomi

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01224769 on ClinicalTrials.gov